Tumours can originate from a stem cell via dedifferentiation, therefore, the use of DNMT inhibitors may reactivate tumour suppressor genes, which could disrupt PGCC-mediated dedifferentiation and the development and progression of tumours [174,175]. Here, DNMT1 is linked to neoplasm.